News | April 23, 2025
Cosmo First to acquire veterinary clinic
The transaction is expected to be completed by May 15, 2025 or such other date as may be mutually agreed
The transaction is expected to be completed by May 15, 2025 or such other date as may be mutually agreed
DESTINY-Breast09 Phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2-positive metastatic patient population versus current 1st-line standard of care
The merged entity ‘Aster DM Quality Care’ will be jointly controlled by Aster Promoters and Blackstone
According to IQVIATM sales data for the 12-month period ending February 2025, the Adderall Tablets, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg market3 achieved annual sales of approximately $421.7 million.
Carbamazepine Tablets USP, 200 mg have an estimated market size of US$ 32 million for twelve months ending December 2024 according to IQVIA
Rising demands and advancements in eye care drive growth
Aarti Pharmalabs becomes 6th Indian Pharma/CDMO to earn SBTi approval for all 3 Scopes since 2022 demerger
The discontinuation decision is only on the basis of commercial reasons and is not due to efficacy or safety reasons
The approved product, Mesalamine Suppositories 1000 mg, has an estimated U.S. market size of US$ 29 million
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
